UCB to buy Zogenix for nearly $2B in ‘first step’ for M&A in 2022
Belgium's UCB on Wednesday said it has agreed to acquire Zogenix for as much as $1.9 billion in a deal centered around an epilepsy drug the California-based biotech b...
Continue Reading →
